 |
|
Effects of Protease Inhibitors on Hyperglycemia, Hyperlipidemia, and Lipodystrophy
A 5-Year Cohort Study
Sotirios Tsiodras, MD;
Christos Mantzoros, MD;
Scott Hammer, MD;
Matthew Samore, MD
Arch Intern Med. 2000;160:2050-2056.
Background Although human immunodeficiency virus (HIV)–related morbidity and mortality rates in patients with advanced HIV infection who are treated with combination antiretroviral drugs have declined, significant metabolic adverse effects associated with these regimens have been increasingly recognized. However, since data from patients studied before and after initiation of protease inhibitor (PI) therapy are scant, the true effect of PIs on these metabolic changes remains unknown.
Objectives To examine temporal trends in serum glucose and lipid levels after initiation of PI therapy, to assess whether changes are independent of virological response and improvement in disease severity, and to determine risk factors associated with the development of hyperglycemia, hyperlipidemia, and lipodystrophy.
Methods A 5-year historical cohort analysis in a population of 221 HIV-infected patients observed in the Infectious Diseases Clinic of a tertiary care center from October 1, 1993, through July 31, 1998. Clinical and laboratory data were retrieved from medical records and a computerized database. The main outcome measure was the incidence of hyperglycemia, hypercholesterolemia, hypertriglyceridemia, and lipodystrophy. Adjusted incidence rate ratios (IRRs) were estimated by means of Poisson regression. In addition, mixed regression analyses were performed to examine effects of PIs on serum lipid and glucose levels, modeled as continuous outcomes.
Results The cumulative incidence of new-onset hyperglycemia, hypercholesterolemia, hypertriglyceridemia, and lipodystrophy was 5%, 24%, 19%, and 13%, respectively. Most of these events occurred after initiation of PI therapy. Protease inhibitors were independently associated with hyperglycemia (adjusted IRR, 5.0; 95% confidence interval [CI], 1.3-19.4), hypercholesterolemia (adjusted IRR, 2.8; 95% CI, 1.5-5.2), hypertriglyceridemia (adjusted IRR, 6.1; 95% CI, 3.1-11.7), and lipodystrophy (adjusted IRR, 5.1; 95% CI, 1.9-13.9). Anabolic steroids and psychotropic medications were also associated with lipodystrophy. Inclusion of potential intermediate variables (eg, virological suppression and increase in body weight) did not reduce the magnitude of the association with PIs. The association between hypertriglyceridemia and ritonavir was stronger than for other PIs (Wald test, P=.02). In contrast, the incidence of hyperglycemia, hypercholesterolemia, and lipodystrophy did not vary significantly across different PIs. Longitudinal mixed models confirmed that serum lipid levels were more substantially affected by antiretroviral therapy, particularly PIs, than serum glucose levels. Similarly, controlling for surrogate markers did not abolish the strong association between PIs and increase in serum lipid levels.
Conclusion We found an independent association between PI use and hyperglycemia, hyperlipidemia, and lipodystrophy that is not explained by the antiviral and therapeutic effect of PIs.
From the Divisions of Infectious Diseases (Drs Tsiodras, Hammer, and Samore) and Endocrinology and Metabolism (Dr Mantzoros), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection
Samaras
J Antimicrob Chemother 2008;61:238-245.
ABSTRACT
| FULL TEXT
Long-Term Treatment with Lopinavir-Ritonavir Induces a Reduction in Peripheral Adipose Depots in Mice
Prot et al.
Antimicrob. Agents Chemother. 2006;50:3998-4004.
ABSTRACT
| FULL TEXT
Recombinant Methionyl Human Leptin Therapy in Replacement Doses Improves Insulin Resistance and Metabolic Profile in Patients with Lipoatrophy and Metabolic Syndrome Induced by the Highly Active Antiretroviral Therapy
Lee et al.
J. Clin. Endocrinol. Metab. 2006;91:2605-2611.
ABSTRACT
| FULL TEXT
Error in Renumbering References in Text and Reference List in: Antiretroviral Therapy and the Prevalence and Incidence of Diabetes Mellitus in the Multicenter AIDS Cohort Study
Arch Intern Med 2005;165:2541-2541.
FULL TEXT
Effects of the Human Immunodeficiency Virus-Protease Inhibitor, Ritonavir, on Basal and Catecholamine-Stimulated Lipolysis
Adler-Wailes et al.
J. Clin. Endocrinol. Metab. 2005;90:3251-3261.
ABSTRACT
| FULL TEXT
Antiretroviral Therapy and the Prevalence and Incidence of Diabetes Mellitus in the Multicenter AIDS Cohort Study
Brown et al.
Arch Intern Med 2005;165:1179-1184.
ABSTRACT
| FULL TEXT
Atazanavir--A Once-daily HIV Protease Inhibitor That Does Not Cause Dyslipidemia in Newly Treated Patients: Results from Two Randomized Clinical Trials
Cahn et al.
J Int Assoc Physicians AIDS Care (Chic Ill) 2004;3:92-98.
ABSTRACT
Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients
Zeldin and Petruschke
J Antimicrob Chemother 2004;53:4-9.
ABSTRACT
| FULL TEXT
Modulation of the LDL receptor and LRP levels by HIV protease inhibitors
Tran et al.
J. Lipid Res. 2003;44:1859-1869.
ABSTRACT
| FULL TEXT
Eruptive Xanthomas Associated With Olanzapine Use
Chang et al.
Arch Dermatol 2003;139:1045-1048.
ABSTRACT
| FULL TEXT
Medical Management of Hyperlipidemia/Dyslipidemia
Kreisberg and Oberman
J. Clin. Endocrinol. Metab. 2003;88:2445-2461.
FULL TEXT
Human Immunodeficiency Virus/Highly Active Antiretroviral Therapy-Associated Metabolic Syndrome: Clinical Presentation, Pathophysiology, and Therapeutic Strategies
Leow et al.
J. Clin. Endocrinol. Metab. 2003;88:1961-1976.
FULL TEXT
Mechanisms for the Deterioration in Glucose Tolerance Associated With HIV Protease Inhibitor Regimens
Woerle et al.
Diabetes 2003;52:918-925.
ABSTRACT
| FULL TEXT
Hypoadiponectinemia Is Associated with Insulin Resistance, Hypertriglyceridemia, and Fat Redistribution in Human Immunodeficiency Virus-Infected Patients Treated with Highly Active Antiretroviral Therapy
Addy et al.
J. Clin. Endocrinol. Metab. 2003;88:627-636.
ABSTRACT
| FULL TEXT
Early Factors in Successful Anti-HIV Treatment
Piliero
J Int Assoc Physicians AIDS Care (Chic Ill) 2003;2:10-20.
ABSTRACT
Lipodystrophy in Human Immunodeficiency Virus-Infected Patients
Chen et al.
J. Clin. Endocrinol. Metab. 2002;87:4845-4856.
ABSTRACT
| FULL TEXT
Incidence of morphological and lipid abnormalities: gender and treatment differentials after initiation of first antiretroviral therapy
Heath et al.
Int J Epidemiol 2002;31:1016-1020.
ABSTRACT
| FULL TEXT
Guidelines for Using Antiretroviral Agents among HIV-Infected Adults and Adolescents: The Panel on Clinical Practices for Treatment of HIV
Dybul et al.
ANN INTERN MED 2002;137:381-433.
ABSTRACT
| FULL TEXT
Effect of Combination Therapy Including Protease Inhibitors on Mortality among Children and Adolescents Infected with HIV-1
Gortmaker et al.
NEJM 2001;345:1522-1528.
ABSTRACT
| FULL TEXT
Drug-Induced Hyperglycemia
Luna and Feinglos
JAMA 2001;286:1945-1948.
FULL TEXT
Impact of Protease Inhibitor-Containing Combination Antiretroviral Therapies on Height and Weight Growth in HIV-Infected Children
Buchacz et al.
Pediatrics 2001;108:e72-72.
ABSTRACT
| FULL TEXT
Use of Human Immunodeficiency Virus-1 Protease Inhibitors Is Associated With Atherogenic Lipoprotein Changes and Endothelial Dysfunction
Stein et al.
Circulation 2001;104:257-262.
ABSTRACT
| FULL TEXT
Adverse metabolic consequences of HIV protease inhibitor therapy: the search for a central mechanism
Hruz et al.
Am. J. Physiol. Endocrinol. Metab. 2001;280:E549-E553.
ABSTRACT
| FULL TEXT
HIV Protease Inhibitors Stimulate Hepatic Triglyceride Synthesis
Lenhard et al.
Arterioscler. Thromb. Vasc. Bio. 2000;20:2625-2629.
ABSTRACT
| FULL TEXT
|
